Testimonial of a Swine ProfessionalThe Protein Sources management team implemented the use of MJPRRS® autogenous vaccine on all of our owned and managed farms about four years ago. Since then we have seen results that have continued to warrant its use. The vaccine has not shown itself to completely eliminate infections or clinical signs in all cases, but it has reduced the initial and residual financial losses. Our evaluations have concluded these minimized losses have been due to reductions in the severity and the duration of the infections. In some cases the product has completely prevented clinical signs. We are very pleased by the results of the vaccine and the service provided by MJ Biologics. We will continue using it as long as we see these results.
Testimonial of a Swine ProfessionalWe at Great Plains Management are using MJPRRS® vaccine and grouping technology at many farms that we manage with PRRS issues. We are very impressed with the response that we are experiencing with time to negative, and in the face of a break the maintained pig quality that we can move down stream. There may never be a silver bullet but MJPRRS vaccine allows us to mitigate the financial effects of PRRS and allows the farm to move forward.
Great Plains Management
Testimonial of a Swine Professional
First, I want to say that MJ Biologics is not compensating me in any manner for this testimonial. I am very willing and eager to share this testimonial, simply because it has really helped two sow farms that I work with.
For many years I have observed how the PRRS virus has caused financial devastation for pig owners; how "abortion storms" have caused depression for sow farm staff; and how "non-responsive" PRRS infected nursery pigs cause depression for nursery staff. We have all been in this spot.
Our consulting veterinarian, Dr. Paul Armbrecht, recommended the MJ product to us three years ago. We are now in our third year and third winter of using the MJ Biologic PRRS product at two Northwest Iowa sow farms. One farm is 2500 sows, and the other farm is 1250 sows. We are very pleased with the results. Every live animal in the sow farm (except pigs on the sow) is given the MJ PRRS product every two months. While this is a significant expense if the product doesn't work .it is a minimal expense if it works. This product has worked for us.
The MJ product will not 100% prevent you from ever having PRRS PCR positive sows or pigs .but, if used correctly, it will GREATLY reduce the severity of any challenge.
I would be glad to visit on the telephone or via email with anyone who would like to hear more of the reasons we are happy with this product.
Testimonial of Swine Health ProfessionalsPike Pig Systems
113 E. Washington Street
Pittsfield, IL 62363
February 2, 2010
In the fall of 2008 we started working with a 4-5 year old 6400-sow farm that had a history of at least two previous PRRS virus outbreaks. Each break followed up with treatment with PRRS serum therapy of both the sow herd and attached GDU. The farm was in the process of trying to eradicate the virus through redesigned animal and personnel flows as well as stricter bio-security procedures. However, after a period of time with poor quality pigs, short pig placements, disgruntled owners, disgruntled workers, and higher costs, the frustration level was at an all-time high. At this time ownership changed their focus from PRRS eradication to improved numbers of good quality pigs regardless of the PRRS status of the pigs or the sow herd. Scrapping the PRRS eradication program led us to explore other PRRS management strategies.
Prior to the use of MJPRRS vaccine:
The farm structure is a 6400 sow breed-wean farm with 2 gestation barns and common farrowing rooms. There are 2 isolation nurseries capable of handling 360 gilts which are delivered (PRRS naïve) to the farm every four weeks at 3-4 weeks of age. After an 8 week stay, the gilts are moved into the gilt grow finish facility that is attached to the sow farm. Once gilts reach 28 weeks of age and have received proper vaccination and acclimation, they are then moved into the breeding/gestation barns. Once the PRRS eradication procedures had been eliminated, the daily foot traffic and chores returned to a more normal farm routine. We also began using a new sub-unit PRRS vaccine as a 2-dose vaccination prior to replacement gilts being introduced into the breeding herd. The new PRRS sub-unit vaccine was the same product that had been given to all sows in weeks 44 and 48 of 2008. Prior to the use of the PRRS sub-unit vaccine, the herd performance was at a 10.85% live born, 4.7% still born rate, 1.9% mummy rate, 17% pre-weaning mortality and 8.7 pigs per sow weaning average.
With these changes we had targeted producing 2700 pigs per week rather than the 1900 to 2100 pigs per week we had produced over the previous nine months. Approximately 12 weeks after beginning the new vaccination program (week 4 of 2009), we started seeing an increase in the pre-weaning mortality, stillborn and mummy rate, and experienced 37 late term abortions. Keeping in mind that all these animals had already received two doses of the new sub-unit PRRS vaccine, we pulled blood out of symptomatic sows in gestation, pigs in farrowing and gilts getting ready to leave the isolation nursery (delivered naïve and sero-converted naturally) after their 8-week stay. We found all three sampled areas yielded 100 percent PRRS PCR positive results. Immediate virus sequencing was done. Samples from all 3 areas of the farm yielded the same PRRS virus. The decision then was made to come back and booster the entire population with another dose of the same, new sub-unit PRRS vaccine on week 8 of 2009.
During that time, we had planned on investigating other possibilities in regard to PRRS management control. We also started testing pigs coming out of the farrowing house 4 weeks after the sow booster of the new sub-unit PRRS vaccine was given. We found pigs to be PRRS positive coming out of farrowing every week that we tested between weeks 13 and 17, 2009. Considering that it had been 6 weeks since the booster of the new sub-unit vaccine had been given, we concluded that it was time to look at our next option.
Use of MJPRRS vaccine:
During our testing we had heard about MJ Biologics, and submitted the 3 strains of PRRS virus sequences for evaluation and characterization of viruses based on MJPRRS® grouping technology to make sure that the virus groups of those isolated would be included in the vaccine that we used. Once we got the vaccine, we used it on the entire sow herd and all the way through isolation (10,000 doses+/-).
When the MJPRRS vaccine was put into the herd we were operating at a 5.5% stillborn rate and 18% mummy rate over the previous 10 weeks. The new sub-unit vaccine that we had used appeared to stop late stage abortions, but did not seem to have an effect on stillborn or mummy rates. The vaccine also appeared to have no effect on limiting PCR status for PRRS virus in pigs at weaning time. The booster (2nd vaccination) of the MJPRRS was given to all sows in the herd on weeks 22 of 2009. Once again all groups being weaned had samples taken from the poorest pigs in the group to do PCR analysis for PRRS virus beginning with week 18 and continuing through week 25.
The summary of information based on records and laboratory analysis appears to be very significant. By the 4th week after the first dose of MJPRRS vaccine, mummy rates had dropped from 19% down to 6.3% and continued to inch its way down to the present level of 1.6%. The stillborn rate also decreased from 5.5% down to 4.5%. Pigs remained PCR positive for PRRS until the 6th week (week 24 of 2009) after the initial vaccination or 2 weeks after the booster. The farm has continued the vaccination program by giving a whole herd booster of the MJPRRS vaccine every 13 weeks. Pigs coming out of the farrowing house remain PCR negative for PRRS from week 24 of 2009 to the present time.
At this point, the MJPRRS approach has resulted in a significant increase in pigs produced each week (2750-2850) as well as a major improvement in pig quality. Owners claimed that a year earlier the pigs they received averaged 70% good, 20% questionable but start-able and 10% of no value. The same owners today rate them 95% excellent pigs, 3% good pigs and 2% off pigs. Performance of the pigs in nurseries and finishers has been exceptional. Due to these results on this farm as well as others where MJPRRS was used, we plan to continue to use this product as our first option.
See more details from the March, 2011 American Association of Swine Veterinarians Presentation
Patrick L. Graham M.S., D.V.M.
John McIntire, General Manager,
and David Bishop, Phd
Testimonial of a Vetrinarian
I am writing to give you my experiences with the use of the autogenous MJPRRS® vaccine. I got involved early in the development phase of the technology, but the actual use of the vaccine started in July 2008. I started and have continued the use of vaccines in over 75,000 sows to control Porcine Reproductive and Respiratory Syndrome (PRRS).
The disease has cost the swine industry hundreds of millions if not billions of dollars in the last 20 years. We have tried and experimented with many solutions including live serum exposure. During that time we failed to find a suitable answer. The use of this vaccine has now given us a potential reprieve for this devastating disease.
I have so far seen results that far exceeded my expectations for the control of PRRS. We have been able to use the vaccine in the face of PRRS disease challenges and saw dramatic results. In specific cases it has been able to prevent the reproductive losses and piglet deaths normally associated with a PRRS break.
A normal goal after a PRRS break is to create piglets that are being born free of the virus. This usually takes 10 to 16 weeks but after the use of MJPRRS vaccine we were able to see it after only 6 weeks.
We have never been able to use a product that has shut down the disease like this before. It has given us totally unexpected results from any procedure or product that we had available to fight this disease in the past.
The technology within the production phase of this vaccine is revolutionary to the swine industry. It will be invaluable in helping us protect the health and well being of the animals under our care and the livelihoods of many hog producers.
The swine industry will be greatly benefitted by the production of this technology as move forward in the 21st century.
I would not look forward to continuing in the next few years without the use of this unique and extraordinary product.
Mark FitzSimmons, DVM
2006 Swine Practitioner-of-the-Year
MAF Veterinary Services
503 Silver Street
Mapleton, MN 56065
Testimonial of a Swine Health Professional
Sow Farm 1
We began using MJPRRS® vaccine on a 3,700 head sow farm that had broken with a 1–?–2 family of PRRS virus (D4). The farm broke in October 2007 and continued to produce PRRS PCR positive weaned pigs through March of 2008 with 15 — 20% wean to finish mortality, despite live virus inoculation and herd closure. At the sow farm in March abortions began to increase and reached a point of 120 — 130 per week before the initial MJPRRS vaccination was delivered. Week one following MJPRRS® vaccination only 80 additional abortions had occurred. The second week after vaccination saw 40 abortions. The third week saw 15 abortions and the following weeks returned to 2 — 4 abortions. The farm has completed their booster vaccinations and is now using a prefarrowing vaccination program with 1 — 2.5% nursery and 2 — 3% finishing mortality.
Sow Farm 2
A farrow–to–finish farm on the eastern fringe of South Dakota was having PRRS recirculation every 5 — 6 months. The clinical signs would begin in the gestation barn and quickly move into the suckling piglets. Eventually the virus would settle in the first 3 — 4 weeks post–weaning and caused repeated seroconversion. Taking a retrospective look at the viral sequences revealed that every 6–month recirculation of the virus was a shift between groups D4 and D5.
We began vaccination with a D1456 S1 began in early January. On January 22nd, about 17 days after the initial MJ PRRS whole herd vaccination, there were increasing abortions and piglet quality in farrowing was deteriorating as well. At this point PRRS was suspected, but the decision was made to booster the herd again. The intent was to hasten the process of immune building/boosting while waiting for a diagnosis. A D6 PRRS (a new introduction) was confirmed and clinical signs in the herd began to slow within 5 — 7 days of the second vaccination.
It was later discovered that this virus matched others from nearby farms and had been tracking through the region for 3 — 4 weeks prior to arrival in this farrow–to–finish unit. The farm repeated the vaccination 6 weeks after the second shot and now maintains immunity with 5 whole herd shots annually. This farm was slightly ahead of the curve with use of a D1456 S1 vaccine and realized about 6% abortions. Neighboring farms with the same virus noticed 10 — 20% abortions and much higher death loss of sows and piglets alike.
Today, the farm is still weaning PRRS negative piglets (since May–June 2012) but the growing piglets are seroconverting to PRRS at 3 — 4 weeks postweaning. A partial depopulation of the nursery in late–August of 2012 provided 12 — 15 pounds per pig during their time in the nursery and intentions are to repeat this process again in late spring of 2013 if piglets are still being weaned negative.
A system receiving rotating sources of pigs and PRRS status was having difficulty controlling mortality and fallback animals throughout the growing cycle. In a short period of time, 3 different PRRS groups had been identified and the next group of animals was due to arrive. The groups were a D4, D6, and an S3.
At the time a gamble was taken to expose the pigs to the PRRS MLV vaccine and follow this up with a single dose of MJ PRRS 3 weeks later D456 S15. The nursery was somewhat isolated from the finishing flow and chores in the nursery were only completed first thing in the morning and after a shower in the afternoon/evening.
The group responded well and had minimal nursery death loss (1.5 — 2.0% ). This group was going to a finishing barn to stand right next to pigs that were just shy of 12% mortality as a group and a similar amount being light. Even without the S3 group in the MJ vaccine, this vaccinated group of animals performed amazingly. The mortality wean–to–finish was just under 5% and this group chased the group 8 weeks older off the site.
Keith Kinsley, DVM
LiManCo - Livestock Management Company
Swine Health Center
Sioux Falls, South Dakota
Testimonial of a Veterinarian
"In my hands, the PRRS products and technical advice from MJ Biologics have been valuable in a balanced approach to controlling the PRRS virus. MJ's grouping system for virus strains has proven itself to be a very useful tool in understanding what is happening in the field in regard to the PRRS virus mutating intra farm and moving from farm to farm.
MJ Biologics' inactivated PRRS vaccine in combination with biosecurity protocols, pig flow restrictions, sanitation have helped me to stabilize active PRRS sow farms as well as keep stabilized farms quiet.
Sow Farm XX is a 3000 sow farrow-to-wean unit located in a hog dense area of southern Minnesota. This farm has used MJPRRS® vaccine for three years very successfully. The young replacement gilts are given live exposure to sero-convert them, then given 2 shots of MJPRRS prior to entering the breeding herd. The sow herd is blanket vaccinated 3 times a year. Prior to MJPRRS, this unit periodically "leaked" PRRS virus to the nursery with subsequent spikes in mortality and morbidity. After the introduction to MJPRRS, the unit has not "leaked" virus in the nursery.
Brian D. Roggow, DVM
Fairmont Veterinary Clinic, LLP
Testimonial of a Veterinarian
I became aware of MJ Biologics in late 2006. After contacting some veterinarians who were using the MJPRRS® vaccine, I decided to try it on my own. In my practice, I work with mostly independent producers who are primarily farrow to finish systems and nearly all dealing with the effects of PRRS.
I had used conventional killed autogenous vaccines with only marginal success and little cross protection. I was frustrated by the unpredictable results of LVI and did not want to use modified live vaccines. The MJ Biologics technology is unique because it provides a mechanism to analyze different viruses to select immunologically different virus strains to broaden the protection in the MJPRRS vaccine.
In 2007, I used this product in 10 farms that had a history of repeated clinical PRRS outbreaks in the past. I began using the vaccine to blanket the sow herd periodically. We were able to prevent prenatal losses, stabilize the sow herds and protect them from outbreaks from new or mutated virus challenges. The number of farms using the vaccine has continued to grow and during the last several years, the vaccine has been applied in many different situations to stabilize herds and get them to produce PCR negative pigs more quickly. Levels of viremia have also been reduced more rapidly.
In 2009 with more product availability we started to use the vaccine in piglets in herds that were producing PCR positive pigs. We were very pleased with the unexpected results that we experienced. In the 20+ year history of the PRRS disease, I have never witnessed a product that would accomplish what MJPRRS has done in reducing death loss and clearing the virus in such a short period of time.
The clinical picture has been dramatically and rapidly improved after vaccination even though some PCR tests in some herds remain positive. The Virus Quantitation tests revealed that vaccinates had 100 to 1000 fold LESS virus in their serum compared to non-vaccinates.
In conjunction with other good production practices, this technology provides the means to produce a multi-strain vaccine with a high antigen content that can reduce the clinical and economic impact of PRRS in a swine herd. My confidence in this technology allows me to continue to apply this product in situations where producers have been dealing with costly effects of PRRS.
Paul J. Armbrecht, DVM
Lake City Veterinary Service
Lake City, Iowa
Testimonial of a Veterinarian
In the past, cross-protection between different strains of PRRS has been sporadic and unpredictable. Protection when re-exposed to the same homogeneous virus is more predictable.
I did a series of trials involving pregnant sows, and the results demonstrated partial to full protection when challenged with a wild type PRRS virus. These sows had a history of prior field PRRS virus exposure and multiple doses of killed MJPRRS® vaccine. The challenge PRRS viruses were at least 8% different from what the sows were exposed to previously. Additionally, each challenge virus used had previously been associated with severe clinical disease in non-related herds.
Preliminary data is positive regarding this new MJPRRS vaccine. Additional trials are planned to confirm these findings. For a more complete summary of these trial results, refer to poster/abstract entitled "Protection against heterologous PRRSV challenge in pregnant sows immunized with multivalent PRRS vaccine" (1).
Mark Wagner, D.V.M.
Fairmont Vet Clinic
1. Wagner M., et al. Protection against heterologous PRRSV challenge in pregnant sows immunized with multivalent PRRSV vaccines. In: International PRRS Symposium, 2005 Dec. 2-3; St. Louis, MO.